Helix BioPharma Corp (HBP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
55
About the Report
About the Report
Summary
Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. It develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company's proprietary broad anti-cancer therapeutic platform has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company's proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Aurora, Ontario, Canada.
Helix BioPharma Corp (HBP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Helix BioPharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Helix BioPharma Plans Partnership For L-DOS47 12
Helix Biopharma Enters into Agreement with ProMab Biotechnologies 13
Helix BioPharma and Moffitt Cancer Center Enter into Agreement 14
Licensing Agreements 15
Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 15
Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 16
Helix Polska Enters into Licensing Agreement with Helix BioPharma 17
Equity Offering 18
Helix BioPharma Raises USD0.3 Million in Private Placement of Units 18
Helix BioPharma Raises USD0.8 Million in Private Placement of Units 19
Helix BioPharma Raises USD0.5 Million in Private Placement of Units 20
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 21
Helix BioPharma Raises USD3 Million in Private Placement of Units 22
Helix BioPharma Raises USD1 Million in Private Placement of Units 23
Helix BioPharma Raises USD2.3 Million in Private Placement of Units 24
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 25
Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 26
Helix BioPharma Raises USD1 Million in Private Placement of Units 27
Helix BioPharma Raises USD1.4 Million in Private Placement of Units 28
Helix BioPharma Raises USD3.58 Million in Private Placement of Units 29
Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 30
Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 31
Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 32
Helix BioPharma Completes Private Placement Of Common Stock And Warrants 33
Asset Transactions 34
Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For USD 8.6 Million 34
Helix BioPharma Corp-Key Competitors 35
Helix BioPharma Corp-Key Employees 36
Helix BioPharma Corp-Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Jun 12, 2018: Helix BioPharma Reports Fiscal Third Quarter 2018 Financial Results 38
Mar 20, 2018: Helix BioPharma Announces Fiscal Second Quarter 2018 Results 40
Dec 13, 2017: Helix BioPharma Announces Fiscal First Quarter 2018 Results 42
Oct 27, 2017: Helix BioPharma Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update 43
Jun 13, 2017: Helix BioPharma Announces Fiscal Third Quarter 2017 Results 45
Mar 17, 2017: Helix BioPharma Announces Fiscal Second Quarter 2017 Results 47
Corporate Communications 48
Mar 22, 2018: Helix BioPharma Welcomes Drs. Daniel Von Hoff, Kazimierz Roszkowski-Sliz and Robert Gillies to Its Scientific and Strategic Advisory Board 48
Dec 01, 2017: Helix BioPharma Announces Management Change 49
Jul 17, 2017: Helix BioPharma Director Resigns 50
Mar 07, 2017: Helix BioPharma Announces Strategic Management Changes 51
Product News 52
04/03/2017: Helix BioPharma to Present CAR-T at AACR Annual Meeting 2017 in Washington, D.C. 52
01/23/2017: Helix BioPharma Announces CAR-T Poster Presentation at AACR Annual Meeting 2017 in Washington, DC 53
Other Significant Developments 54
Sep 12, 2018: Helix BioPharma collaborator ProMab Biotechnologies publishes paper on multiple myeloma CAR-T 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
List of Figure
List of Figures
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Helix BioPharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Helix BioPharma Plans Partnership For L-DOS47 12
Helix Biopharma Enters into Agreement with ProMab Biotechnologies 13
Helix BioPharma and Moffitt Cancer Center Enter into Agreement 14
Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 15
Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 16
Helix Polska Enters into Licensing Agreement with Helix BioPharma 17
Helix BioPharma Raises USD0.3 Million in Private Placement of Units 18
Helix BioPharma Raises USD0.8 Million in Private Placement of Units 19
Helix BioPharma Raises USD0.5 Million in Private Placement of Units 20
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 21
Helix BioPharma Raises USD3 Million in Private Placement of Units 22
Helix BioPharma Raises USD1 Million in Private Placement of Units 23
Helix BioPharma Raises USD2.3 Million in Private Placement of Units 24
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 25
Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 26
Helix BioPharma Raises USD1 Million in Private Placement of Units 27
Helix BioPharma Raises USD1.4 Million in Private Placement of Units 28
Helix BioPharma Raises USD3.58 Million in Private Placement of Units 29
Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 30
Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 31
Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 32
Helix BioPharma Completes Private Placement Of Common Stock And Warrants 33
Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For USD 8.6 Million 34
Helix BioPharma Corp, Key Competitors 35
Helix BioPharma Corp, Key Employees 36
Helix BioPharma Corp, Subsidiaries 37
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.